SURF
Price:
$1.07
Market Cap:
$65.08M
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement ...[Read more]
Industry
Biotechnology
IPO Date
2018-04-19
Stock Exchange
NASDAQ
Ticker
SURF
According to Surface Oncology, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 59.73M. This represents a change of 6.67% compared to the average of 55.99M of the last 4 quarters.
The mean historical Enterprise Value of Surface Oncology, Inc. over the last ten years is 132.84M. The current 59.73M Enterprise Value has changed 4.40% with respect to the historical average. Over the past ten years (40 quarters), SURF's Enterprise Value was at its highest in in the September 2021 quarter at 328.65M. The Enterprise Value was at its lowest in in the December 2018 quarter at -41454840.00.
Average
132.84M
Median
212.75M
Minimum
-74073160.00
Maximum
247.79M
Discovering the peaks and valleys of Surface Oncology, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 639.15%
Maximum Annual Enterprise Value = 247.79M
Minimum Annual Increase = -141.38%
Minimum Annual Enterprise Value = -74073160.00
Year | Enterprise Value | Change |
---|---|---|
2022 | 50.85M | -76.10% |
2021 | 212.75M | -6.10% |
2020 | 226.56M | 639.15% |
2019 | 30.65M | -141.38% |
2018 | -74073160.00 | -131.48% |
2017 | 235.33M | -5.03% |
The current Enterprise Value of Surface Oncology, Inc. (SURF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
163.39M
5-year avg
89.35M
10-year avg
132.84M
Surface Oncology, Inc.’s Enterprise Value is greater than Syros Pharmaceuticals, Inc. (22.19M), greater than Repare Therapeutics Inc. (42.05M), less than Personalis, Inc. (284.58M), greater than Evogene Ltd. (6.30M), less than Iovance Biotherapeutics, Inc. (2.89B),
Company | Enterprise Value | Market cap |
---|---|---|
22.19M | $40.49M | |
42.05M | $119.70M | |
284.58M | $285.67M | |
6.30M | $14.97M | |
2.89B | $3.04B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Surface Oncology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Surface Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Surface Oncology, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Surface Oncology, Inc. (SURF)?
What is the 3-year average Enterprise Value for Surface Oncology, Inc. (SURF)?
What is the 5-year average Enterprise Value for Surface Oncology, Inc. (SURF)?
How does the current Enterprise Value for Surface Oncology, Inc. (SURF) compare to its historical average?